(PDF) The ABL Switch Control Inhibitor DCC-2036 Is Active

The ABL Switch Control Inhibitor DCC-2036 Is Active Against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile

Cancer Research - United States

doi 10.1158/0008-5472.can-10-3224

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

April 19, 2011

Authors

M. W. N. Deininger

Publisher

American Association for Cancer Research (AACR)

Related search

CT-721, a Potent BCR-Abl Inhibitor, Exhibits Excellent in Vitro and in Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Journal of Cancer

English

Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

English

Chronic Myeloid Leukemia Stem Cells Possess Multiple Unique Features of Resistance to BCR-ABL Targeted Therapies

Cancer Research

English

Acute Myeloid Leukemia With BCR/ABL Fusion Chimera

Indian Journal of Hematology and Blood Transfusion

English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research

Cancer Research

English

Management of Chronic Myeloid Leukemia With BCR/ABL Inhibitors: Current Status and Future Perspectives

Clinical Medicine Insights: Therapeutics

Pharmaceutical Science

English

Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571

Clinical Cancer Research

Cancer Research

English

Adoptive Immunotherapy of BCR-ABL-induced Chronic Myeloid Leukemia-Like Myeloproliferative Disease in a Murine Model

English